Yiquan Xu

516 total citations
27 papers, 338 citations indexed

About

Yiquan Xu is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yiquan Xu has authored 27 papers receiving a total of 338 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 12 papers in Oncology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yiquan Xu's work include Lung Cancer Treatments and Mutations (5 papers), Brain Metastases and Treatment (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Yiquan Xu is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Brain Metastases and Treatment (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Yiquan Xu collaborates with scholars based in China, United States and Austria. Yiquan Xu's co-authors include Junfan Pan, Zhidong Huang, Yusheng Chen, Nan Yang, Yang Li, Chao Li, Guang Wang, Yan Jin, Yin Ding and Caiyun Zhang and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and IEEE Transactions on Geoscience and Remote Sensing.

In The Last Decade

Yiquan Xu

24 papers receiving 335 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yiquan Xu China 9 224 156 83 76 62 27 338
Andrzej Tysarowski Poland 11 145 0.6× 53 0.3× 117 1.4× 99 1.3× 24 0.4× 36 315
Fenfen Zhang China 10 204 0.9× 124 0.8× 72 0.9× 89 1.2× 29 0.5× 19 351
Shengda Cao China 12 229 1.0× 179 1.1× 46 0.6× 42 0.6× 31 0.5× 30 302
Mehmet Buğrahan Düz Türkiye 8 190 0.8× 144 0.9× 71 0.9× 39 0.5× 27 0.4× 17 288
Claudia Gedlicka Austria 12 157 0.7× 48 0.3× 244 2.9× 91 1.2× 84 1.4× 16 383
Junya Ueda Japan 3 88 0.4× 107 0.7× 63 0.8× 50 0.7× 49 0.8× 3 282
Carmen Etxezarraga Spain 9 65 0.3× 46 0.3× 158 1.9× 38 0.5× 76 1.2× 15 234
Ruohao Fan China 11 70 0.3× 34 0.2× 66 0.8× 62 0.8× 112 1.8× 35 366
Chung-Jan Kang Taiwan 5 141 0.6× 137 0.9× 65 0.8× 68 0.9× 74 1.2× 10 307
Xianzheng Gao China 10 211 0.9× 173 1.1× 80 1.0× 53 0.7× 28 0.5× 22 333

Countries citing papers authored by Yiquan Xu

Since Specialization
Citations

This map shows the geographic impact of Yiquan Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yiquan Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yiquan Xu more than expected).

Fields of papers citing papers by Yiquan Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yiquan Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yiquan Xu. The network helps show where Yiquan Xu may publish in the future.

Co-authorship network of co-authors of Yiquan Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Yiquan Xu. A scholar is included among the top collaborators of Yiquan Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yiquan Xu. Yiquan Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pan, Junfan, Yuan Zhang, He Liu, et al.. (2024). CHAC1 blockade suppresses progression of lung adenocarcinoma by interfering with glucose metabolism via hijacking PKM2 nuclear translocation. Cell Death and Disease. 15(10). 728–728. 5 indexed citations
2.
Lee, Jang‐Ming, et al.. (2024). P4.07D.04 Trofuse-019: A Phase 3 Study of Adjuvant Pembrolizumab with or without Sac-TMTfor Resectable Stage II-IIIB (N2) NSCLC. Journal of Thoracic Oncology. 19(10). S378–S378.
3.
Pircher, Andreas, Michael A. W. Eaton, Atsushi Hata, et al.. (2024). 117O Stereotactic body radiotherapy (SBRT) with pembrolizumab (pembro) for unresected stage I/II non-small cell lung cancer (NSCLC): The randomized, double-blind, phase III KEYNOTE-867 study. Immuno-Oncology Technology. 24. 100746–100746. 3 indexed citations
4.
Xu, Yiquan. (2024). Single-cell landscape of the immune microenvironment of leptomeningeal metastases in non-small cell lung cancer treated with pemetrexed sheath injection.. Journal of Clinical Oncology. 42(16_suppl). e20026–e20026. 1 indexed citations
5.
Jiang, Kan, Lin Wu, Yiquan Xu, et al.. (2024). Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study. BMC Pulmonary Medicine. 24(1). 96–96. 1 indexed citations
6.
7.
Miao, Qian, Lifeng Li, Xiaobin Zheng, et al.. (2023). Cerebrospinal fluid circulating tumor DNA contributes to the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer. Journal of Neuro-Oncology. 165(3). 517–525. 5 indexed citations
8.
Hong, Yaping, Qian Miao, Yiquan Xu, et al.. (2023). Effects of intrathecal pemetrexed on the survival of patients with leptomeningeal metastasis from lung adenocarcinoma: a propensity score matching analysis. Journal of Neuro-Oncology. 165(2). 301–312. 4 indexed citations
9.
Pan, Junfan, Zhidong Huang, Yuan Zhang, & Yiquan Xu. (2022). ADAM12 as a Clinical Prognostic Indicator Associated with Tumor Immune Infiltration in Lung Adenocarcinoma. DNA and Cell Biology. 41(4). 410–423. 4 indexed citations
10.
Lu, Tao, Kan Jiang, Longfeng Zhang, et al.. (2022). Tumour response heterogeneity as a powerful independent predictor of treatment outcome in advanced lung adenocarcinoma: a retrospective analysis. The Lancet Oncology. 23. S13–S13. 1 indexed citations
11.
Pan, Junfan, Zhidong Huang, & Yiquan Xu. (2021). m5C-Related lncRNAs Predict Overall Survival of Patients and Regulate the Tumor Immune Microenvironment in Lung Adenocarcinoma. Frontiers in Cell and Developmental Biology. 9. 671821–671821. 46 indexed citations
12.
Pan, Junfan, Zhidong Huang, & Yiquan Xu. (2021). m5C RNA Methylation Regulators Predict Prognosis and Regulate the Immune Microenvironment in Lung Squamous Cell Carcinoma. Frontiers in Oncology. 11. 657466–657466. 86 indexed citations
13.
Zhang, Yuan, Jianbo Chen, Yunan Zhao, Lihong Weng, & Yiquan Xu. (2020). Ceramide Pathway Regulators Predict Clinical Prognostic Risk and Affect the Tumor Immune Microenvironment in Lung Adenocarcinoma. Frontiers in Oncology. 10. 562574–562574. 6 indexed citations
14.
Xu, Yiquan, Lihong Weng, Dongmei Zheng, et al.. (2020). Single nucleotide polymorphisms within the Wnt pathway predict the risk of bone metastasis in patients with non-small cell lung cancer. Aging. 12(10). 9311–9327. 9 indexed citations
15.
Xu, Yiquan, et al.. (2019). Morphine contributed to the deterioration of cancer via miR-543/MARCKS/FcγR-mediated phagocytosis pathway. Journal of Pharmacy and Pharmacology. 71(10). 1584–1598. 8 indexed citations
16.
17.
Liu, Hong, Jiao Pei, Yuxin He, et al.. (2016). Comparison of functional change in parotid gland after surgical excision of pleomorphic adenoma by two different types of parotidectomy. Oral Surgery Oral Medicine Oral Pathology and Oral Radiology. 122(4). 385–391. 7 indexed citations
18.
Li, Chao, Yiquan Xu, Caiyun Zhang, et al.. (2013). Modified partial superficial parotidectomy versus conventional superficial parotidectomy improves treatment of pleomorphic adenoma of the parotid gland. The American Journal of Surgery. 208(1). 112–118. 42 indexed citations
19.
Xu, Yiquan, Chao Li, Bing Zhang, et al.. (2012). [Evidence for determining the safe surgical margin for pleomorphic adenoma of parotid gland].. PubMed. 47(2). 137–41. 4 indexed citations
20.
Li, Chao, Bin Li, Jianchao Chen, et al.. (2011). [Meta-analysis of surgical techniques for preventing Frey syndrome and a concave facial deformity after parotidectomy].. PubMed. 46(7). 580–5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrzej Tysarowski Breakdown of academic impact, for papers by Fenfen Zhang Breakdown of academic impact, for papers by Shengda Cao Breakdown of academic impact, for papers by Mehmet Buğrahan Düz Breakdown of academic impact, for papers by Claudia Gedlicka Breakdown of academic impact, for papers by Junya Ueda Breakdown of academic impact, for papers by Carmen Etxezarraga Breakdown of academic impact, for papers by Ruohao Fan Breakdown of academic impact, for papers by Chung-Jan Kang Breakdown of academic impact, for papers by Xianzheng Gao
Rankless by CCL
2026